Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the ...

Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 ...

These proteins, called MDM2 and MDMX, become overactive in cancer and break down p53. Researchers have developed drugs to block MDM2 or MDMX, but targeting just one of these proteins is often not ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

The Purdue College of Veterinary Medicine picked a new associate dean for research, Dr. Susan Mendrysa, which became ...

Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...

A United States-based Nigerian doctoral researcher in systems biology and immunology, Prosper Chukwuemeka, is advancing cancer research by combining computational tools with biology.

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

Learn more about whether Kymera Therapeutics, Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ ...